PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 12 | 3 | 187-192
Article title

Perwityna, „krystaliczna metamfetamina” – nowe zagrożenie na polskiej scenie narkotykowej

Content
Title variants
EN
Pervitin, crystalline methamphetamine – a new threat to the Polish drug scene
Languages of publication
PL
Abstracts
EN
The term pervitin refers to methamphetamine in Central Europe, illegally produced from ephedrine or pseudoephedrine as a precursor. A growth in the use of psychoactive substances in some European countries has been noted for several years. According to data from the European Monitoring Centre for Drugs and Drug Addiction, the number of addicted people to pervitin increases in Europe at a rate of several percent per year. Pervitin is illegally produced and sold especially in the Czech Republic and Slovakia, Germany and the Scandinavian countries, where its use is a significant social and healthcare problem. In Poland, the use of pervitin to intoxication were observed mainly in the provinces of southern and south-west, to which this substance is generally imported from the Czech Republic and Slovakia. Use of pervitin leads to addiction and a number of negative health consequences associated with its influence on the central and peripheral nervous system, cardiovascular and respiratory systems. In the course of pervitin use psychosis caused by intoxication, depression, neuropsychological deficits and damage to various organs may occur. Acute poisoning by pervitin can lead to death due to cardiovascular disorders, or hyperthermia and injecting promotes the spread of blood-borne diseases. The negative effects of its use are also described, such as risky sexual behaviours and crime. The purpose of this article is to draw attention to the relatively new problem of using pervitin in Poland (the so-called Czech crystalline methamphetamine) to intoxication and to describe, among other things, the actions of the substance and the risks arising from its use.
PL
Terminem perwityna określa się w Europie Środkowej metamfetaminę wyprodukowaną nielegalnie z efedryny lub pseudoefedryny, jako prekursora. Od kilkunastu lat notuje się w niektórych krajach europejskich zwiększone zainteresowanie używaniem tej substancji psychoaktywnej. Dane Europejskiego Centrum Monitorowania Narkotyków i Narkomanii wskazują, że liczba osób uzależnionych od perwityny w Europie zwiększa się w tempie kilku procent rocznie. Perwityna jest produkowana i sprzedawana nielegalnie zwłaszcza na terenie Czech i Słowacji oraz w Niemczech i w krajach skandynawskich, gdzie jej przyjmowanie stanowi znaczny problem społeczny i medyczny. W Polsce stosowanie perwityny w celu odurzenia zaobserwowano głównie w województwach południowych i południowo- zachodnich, do których substancja ta jest sprowadzana najczęściej z Czech i Słowacji. Używanie perwityny prowadzi do uzależnienia i wielu negatywnych następstw zdrowotnych związanych z jej działaniem na ośrodkowy i obwodowy układ nerwowy, układ krążenia i układ oddechowy. W przebiegu stosowania perwityny mogą występować psychozy intoksykacyjne, zaburzenia depresyjne i deficyty neuropsychologiczne oraz uszkodzenia różnych narządów wewnętrznych. Ostre zatrucie perwityną może prowadzić do zgonu z powodu zaburzeń układu krążenia lub hipertermii, a jej dożylne przyjmowanie sprzyja rozprzestrzenianiu się chorób przenoszonych drogą krwi. Opisywane są też takie negatywne efekty jej stosowania, jak ryzykowne zachowania seksualne i przestępstwa. Celem tego artykułu jest zwrócenie uwagi na stosunkowo nowy w Polsce problem używania perwityny (tzw. czeskiej, krystalicznej metamfetaminy) w celu odurzenia oraz opisanie działania tej substancji i zagrożeń wynikających z jej stosowania.
Discipline
Publisher

Year
Volume
12
Issue
3
Pages
187-192
Physical description
Contributors
  • Pracownia Badań Biologicznych w Psychiatrii, Klinika Zaburzeń Afektywnych i Psychotycznych Uniwersytetu Medycznego w Łodzi, tzn_lodz@post.pl
References
  • 1. Ling W., Rawson R., Shoptaw S., Ling W.: Management of methamphetamine abuse and dependence. Curr. Psychiatry Rep. 2006; 8: 345-354.
  • 2. Anglin M.D., Burke C., Perrochet B. i wsp.: History of the methamphetamine problem. J. Psychoactive Drugs 2000; 32: 137-141.
  • 3. World Health Organization (WHO): Amphetamine-Type Stimulants: A Report from the WHO Meeting on Amphetamines, MDMA and Other Psychostimulants. World Health Organization, Geneva 1997.
  • 4. Csémy L., Kubicka L., Nociar A.: Drug scene in the Czech Republic and Slovakia during the period of transformation. Eur. Addict. Res. 2002; 8: 159-165.
  • 5. United Nations Office on Drugs and Crime (UNODC): World Drug Report 2005. Adres: http://www.unodc.org/unodc/en/ data-and-analysis/WDR-2005.html, 2006.
  • 6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Amphetamine-type stimulants: indicators of the scope of their use in the EU member states, candidate countries and Norway. Possible connections with HIV epidemic. Presentation at EMCDDA Conference, Vienna, 9-10 March, 2006.
  • 7. Substance Abuse and Mental Health Services Administration: Results from the 2005 National Survey on Drug Use and Health: National Findings (NSDUH Series H-30, DHHS Publication No. SMA 06-4194). Office of Applied Studies, Rockville, MD 2006.
  • 8. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Problem Amphetamine and Methamphetamine Use in Europe. EMCDDA, Lisbon 2010.
  • 9. Härtel-Petri R., Rodler R., Schmeisser U. i wsp.: Increasing prevalence of amphetamine- and methamphetamine-induced psychosis. Psychiatr. Prax. 2005; 32: 13-17.
  • 10. Mravčík V., Korčišová B., Lejčková P. i wsp.: Annual Report: The Czech Republic – 2004 Drug Situation. Office of the Government of the Czech Republic, Prague 2005.
  • 11. Klusonová H., Vlková J., Visnovský P.: Natural opium as one of the possibilities for drug abusers. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2005; 149: 481-483.
  • 12. Gonzalez Castro F., Barrington E.H., Walton M.A., Rawson R.A.: Cocaine and methamphetamine: differential addiction rates. Psychol. Addict. Behav. 2000; 14: 390-396.
  • 13. Nordahl T.E., Salo R., Leamon M.: Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J. Neuropsychiatry Clin. Neurosci. 2003; 15: 317-325.
  • 14. Barr A.M., Panenka W.J., MacEwan G.W. i wsp.: The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 2006; 31: 301-313.
  • 15. Drevets W.C., Gautier C., Price J.C. i wsp.: Amphetamineinduced dopamine release in human ventral striatum correlates with euphoria. Biol. Psychiatry 2001; 49: 81-96.
  • 16. Kokoshka J.M., Metzger R.R., Wilkins D.G. i wsp.: Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res. 1998; 799: 78-83.
  • 17. Kish S.J.: Pharmacologic mechanisms of crystal meth. CMAJ 2008; 178: 1679-1682.
  • 18. Brown J.M., Hanson G.R., Fleckenstein A.E.: Methamphetamine rapidly decreases vesicular dopamine uptake. J. Neurochem. 2000; 74: 2221-2223.
  • 19. Volkow N.D., Chang L., Wang G.J. i wsp.: Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 2001; 158: 377-382.
  • 20. Volz T.J., Hanson G.R., Fleckenstein A.E.: The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J. Neurochem. 2007; 101: 883-888.
  • 21. Zaczek R., Culp S., De Souza E.B.: Intrasynaptosomal sequestration of [3H]amphetamine and [3H]methylenedioxyamphetamine: characterization suggests the presence of a factor responsible for maintaining sequestration. J. Neurochem. 1990; 54: 195-204.
  • 22. Cass W.A.: Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J. Pharmacol. Exp. Ther. 1997; 280: 105-113.
  • 23. Chang L., Alicata D., Ernst T., Volkow N.: Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007; 102 supl. 1: 16-32.
  • 24. Wilson J.M., Kalasinsky K.S., Levey A.I. i wsp.: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996; 2: 699-703.
  • 25. Islam M.N., Kuroki H., Hongcheng B. i wsp.: Cardiac lesions and their reversibility after long term administration of methamphetamine. Forensic Sci. Int. 1995; 75: 29-43.
  • 26. Matoba R.: Cardiac lesions in methamphetamine abusers. Nihon Hoigaku Zasshi 2001; 55: 321-330.
  • 27. Ernst T., Chang L., Leonido-Yee M., Speck O.: Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 2000; 54: 1344-1349.
  • 28. Kim S.J., Lyoo I.K., Hwang J. i wsp.: Prefrontal grey-matter changes in short-term and long-term abstinent methamphetamine abusers. Int. J. Neuropsychopharmacol. 2006; 9: 221-228.
  • 29. Sung Y.H., Cho S.C., Hwang J. i wsp.: Relationship between N-acetyl-aspartate in gray and white matter of abstinent methamphetamine abusers and their history of drug abuse: a proton magnetic resonance spectroscopy study. Drug Alcohol Depend. 2007; 88: 28-35.
  • 30. Hanson G.R., Sandoval V., Riddle E., Fleckenstein A.E.: Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Ann. N. Y. Acad. Sci. 2004; 1025: 146-150.
  • 31. Hart C.L., Ward A.S., Haney M. i wsp.: Methamphetamine selfadministration by humans. Psychopharmacology (Berl.) 2001; 157: 75-81.
  • 32. Schifano F., Corkery J.M., Cuffolo G.: Smokable (“ice”, “crystal meth”) and non smokable amphetamine-type stimulants: clinical pharmacological and epidemiological issues, with special reference to the UK. Ann. Ist. Super. Sanita 2007; 43: 110-115.
  • 33. Cretzmeyer M., Sarrazin M.V., Huber D.L. i wsp.: Treatment of methamphetamine abuse: research findings and clinical directions. J. Subst. Abuse Treat. 2003; 24: 267-277.
  • 34. Comer S.D., Hart C.L., Ward A.S. i wsp.: Effects of repeated oral methamphetamine administration in humans. Psychopharmacology (Berl.) 2001; 155: 397-404.
  • 35. Frosch D., Shoptaw S., Huber A. i wsp.: Sexual HIV risk among gay and bisexual male methamphetamine abusers. J. Subst. Abuse Treat. 1996; 13: 483-486.
  • 36. Gay G.R., Sheppard C.W.: Sex in the “drug culture”. Med. Aspects Hum. Sex. 1972; 6: 28-50.
  • 37. Busto U., Bendayan R., Sellers E.M.: Clinical pharmacokinetics of non-opiate abused drugs. Clin. Pharmacokinet. 1989; 16: 1-26.
  • 38. Zweben J.E., Cohen J.B., Christian D. i wsp.; Methamphetamine Treatment Project: Psychiatric symptoms in methamphetamine users. Am. J. Addict. 2004; 13: 181-190.
  • 39. Jaehne E.J., Salem A., Irvine R.J.: Pharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology (Berl.) 2007; 194: 41-52.
  • 40. Hong R., Matsuyama E., Nur K.: Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991; 265: 1152-1154.
  • 41. Rothrock J.F., Rubenstein R., Lyden P.D.: Ischemic stroke associated with methamphetamine inhalation. Neurology 1988; 38: 589-592.
  • 42. Buffenstein A., Heaster J., Ko P.: Chronic psychotic illness from methamphetamine. Am. J. Psychiatry 1999; 156: 662.
  • 43. Dore G., Sweeting M.: Drug-induced psychosis associated with crystalline methamphetamine. Australas. Psychiatry 2006; 14: 86-89.
  • 44. Domier C.P., Simon S.L., Rawson R.A. i wsp.: A comparison of injecting and noninjecting methamphetamine users. J. Psychoactive Drugs 2000; 32: 229-232.
  • 45. Kalechstein A.D., Newton T.F., Green M.: Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J. Neuropsychiatry Clin. Neurosci. 2003; 15: 215-220.
  • 46. Hoffman W.F., Moore M., Templin R. i wsp.: Neuropsychological function and delay discounting in methamphetamine-dependent individuals. Psychopharmacology (Berl.) 2006; 188: 162-170.
  • 47. Beránková K., Habrdová V., Balíková M., Strejc P.: Methamphetamine in hair and interpretation of forensic findings in a fatal case. Forensic Sci. Int. 2005; 153: 93-97.
  • 48. Davis G.G., Swalwell C.I.: Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse. J. Forensic Sci. 1994; 39: 1481-1485.
  • 49. Davey M.: Grisly effect of one drug: ‘meth mouth’. New York Times, June 11, 2005.
  • 50. Smith L.M., LaGasse L.L., Derauf C. i wsp.: The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 2006; 118: 1149-1156.
  • 51. Barr A.M., Markou A., Phillips A.G.: A ‘crash’ course on psychostimulant withdrawal as a model of depression. Trends Pharmacol. Sci. 2002; 23: 475-482.
  • 52. Logan B.K., Fligner C.L., Haddix T.: Cause and manner of death in fatalities involving methamphetamine. J. Forensic Sci. 1998; 43: 28-34.
  • 53. Baskin-Sommers A., Sommers I.: The co-occurrence of substance use and high-risk behaviors. J. Adolesc. Health 2006; 38: 609-611.
  • 54. Gonzales R., Marinelli-Casey P., Shoptaw S. i wsp.: Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J. Subst. Abuse Treat. 2006; 31: 195-202.
  • 55. Hutin Y.J., Sabin K.M., Hutwagner L.C. i wsp.: Multiple modes of hepatitis A virus transmission among methamphetamine users. Am. J. Epidemiol. 2000; 152: 186-192.
  • 56. Molitor F., Truax S.R., Ruiz J.D., Sun R.K.: Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West. J. Med. 1998; 168: 93-97.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-c43f27f4-963a-4ae3-b4a5-41bd9967f2b5
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.